Boston Scientific Corporation $BSX Shares Sold by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 54.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 35,611 shares of the medical equipment provider’s stock after selling 42,170 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Boston Scientific were worth $3,823,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BSX. 1248 Management LLC bought a new stake in shares of Boston Scientific during the first quarter valued at about $26,000. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares in the last quarter. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter worth about $27,000. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Boston Scientific by 72.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 145 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $102.73 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The firm’s 50 day simple moving average is $99.72 and its 200-day simple moving average is $102.56. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market cap of $152.30 billion, a P/E ratio of 54.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. BTIG Research reissued a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Leerink Partners boosted their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $123.77.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 175,782 shares of company stock valued at $17,742,314 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.